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in the upper and lower limbs (childhood myositis assessment
score of 14/52).5
General exams were performed with the following results:
hemoglobin of 10.4 g/dl, 4400 leucocytes with a normalntroduction
evic’s disease, also known as neuromyelitis optica, is classi-
ed as an autoimmune inﬂammatory demyelinating disorder
f the central nervous system, distinct from multiple scle-
osis, that mainly affects the optic nerve and spinal cord.1
evic’s disease was demonstrated to be the result of antibod-
es against the water channel aquaporin-4 in the blood–brain
arrier.2
There have been reports of Devic’s disease in infancy,3,4
ut there are few reported associations of Devic’s dis-
ase with other diseases. The association of Devic’s disease
ith dermatomyositis has not yet been described in the
iterature.Please cite this article in press as: Fraga MM, et al. Devic’s disease in an ado
http://dx.doi.org/10.1016/j.rbre.2014.12.004
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icenses/by-nc-nd/4.0/).Case  report
A female patient sought our service at 7 years of age, pre-
senting with bipalpebral edema with ocular hyperemia over
the previous 4 months. She also presented edema of the hands
and feet; pain in the wrists, elbows and knees; and muscu-
lar weakness. She also had, on that occasion, an intermittent
fever lasting 15 days.
The physical exam revealed heliotrope, Gottron’s sign,
arthritis in the left knee and ankle, and muscular weaknesslescent girl with juvenile dermatomyositis. Rev Bras Reumatol. 2016.
e under the CC BY-NC-ND license (http://creativecommons.org/
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Fig. 1 – Sagittal magnetic resonance image. T2-weighted
cervical spinal cord showing a long hyperintense spinal
cord lesion (black arrow) in an adolescent girl with juvenile2  r e v b r a s r e u m a t o
differential, erythrocyte sedimentation rate of 70 mm in the
ﬁrst hour, and an increase in muscular enzymes (aspartate
alanine transferase 712 [normal value 10 up to 35], creatine
kinase 187 [normal value 10 up to 155] and lactate dehydroge-
nase 1150 [normal value 240 up to 480]).
Assays for antinuclear antibodies, anti-DNA antibodies,
anti-ENA (extractable nuclear antigens) antibodies and anti-
cardiolipin antibodies were negative, and the complement
level was normal. A muscle biopsy showed perifascicular atro-
phy typical of dermatomyositis. The videodeglutogram was
normal, and a nailfold capillaroscopy demonstrated a sclero-
derma pattern with signiﬁcant capillary deletion and ectasia.
A diagnosis of juvenile dermatomyositis was made.6
Over two years, the patient received 11 pulse thera-
pies of methylprednisolone, prednisone and methotrexate
until clinical and laboratory control of the dermatomyosi-
tis was achieved. The patient abandoned treatment for 4
years, then she returned to the pediatric rheumatology clinic
four years ago, at age of 13, with no clinical (childhood
myositis assessment score 41/52)5 nor laboratory evidence
of juvenile dermatomyositis activity and no medication was
needed.
Two years ago, at age of 15, the patient had numbness
in the left arm without muscular weakness that lasted for
10 days and resolved spontaneously. After two months, the
patient developed paresthesia with proximal and distal mus-
cular weakness in all four limbs, and difﬁculty in walking and
carrying out daily activities. The neurologist ordered a brain
computerized tomography that was normal and no medica-
tion was prescribed. The patient lost the follow up again and
after nine months of these initial symptoms, the patient had
an episode of blurred vision and distal weakness in all four
limbs.
The neurological examination revealed hyperactive deep
tendon reﬂexes in right upper limb and legs, without weak-
ness, and a severe loss of vision in the right eye (VA 20/800)
with fundus examination showing optic disk atrophy. The
expanded disability status scale (EDSS)7 that quantiﬁes dis-
ability in eight functional systems (pyramidal, cerebellar,
brainstem, sensory, bowel and bladder, visual, cerebral and
others) was 4 from a scale of 0 to 10.
Laboratory tests including cerebrospinal ﬂuid analysis
showed no abnormalities. A neurological consultation sug-
gested central nervous system demyelination, and the
neuraxis magnetic resonance image  showed a long intraspinal
lesion from C3 to T4 (Figs. 1 and 2). A proposed diagnosis of
Devic’s disease (neuromyelitis optica) was made. The positive
test for anti-aquaporin 4 antibody conﬁrmed the diagnosis.
The patient was started immediately on pulse therapy with
methylprednisolone followed by azathioprine plus prednisone
as maintenance therapy.
The patient remained stable for eight months with the ini-
tial therapeutic regimen. A year ago, the patient presented
a new outbreak of severe optic neuritis without muscu-
lar weakness but with impaired urinary sphincter function.
Cerebrospinal ﬂuid analysis and brain magnetic resonancePlease cite this article in press as: Fraga MM, et al. Devic’s disease in an ado
http://dx.doi.org/10.1016/j.rbre.2014.12.004
imaging were repeated. She was treated with intravenous
immunoglobulin. Pulse therapy with methylprednisolone
and the use of prednisone 0.1 mg/kg/day and azathioprine
3 mg/kg/day were maintained for four years up to now. Afterdermatomyositis.
immunoglobulin treatment, the patient’s urinary and visual
symptoms improved.
The patient has been in remission for juvenile dermato-
myositis activity for the last four years but still with activity
of the neuromyelitis optica.
Discussion
Recurrent neuromyelitis optica is typically characterized
by visual and spinal cord relapses. Clinical and labora-
tory neuroimaging data and the immunopathology suggest
that neuromyelitis optica differs from multiple sclerosis
and presents a poorer prognosis, making early diagnosis
of paramount importance for the initiation of aggressivelescent girl with juvenile dermatomyositis. Rev Bras Reumatol. 2016.
immunosuppressive therapy.8
New diagnostic criteria have been proposed by Winger-
chuk et al., and these include optic neuritis, acute myelitis,
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Fig. 2 – Axial magnetic resonance image of the cervical
spine (C3) showing a long hyperintense spinal cord lesion
(black arrow) in an adolescent girl with juvenile
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parts). N Engl J Med. 1975;292:344–7, 403–7.ermatomyositis.
nd at least 2 of the 3 following criteria: lesions in the
pinal cord spanning at least three segments on magnetic
esonance images, brain magnetic resonance images incom-
atible with multiple sclerosis and a positive neuromyelitis
ptica IgG test (serum marker: auto-antibody directed against
quaporin-4).9
Anti-aquaporin 4 is an autoantibody (IgG) targeted against
he water channels of the blood–brain barrier, and the SNC
esion distribution corresponds to the areas where there
s a high concentration of such channels. Therefore, anti-
quaporin-4 may be considered a biomarker for neuromyelitis
ptica, although the extent of the correlation between the titer
f the antibody and the relapse severity is not clear. 9
Luccinetti et al. demonstrated the deposition of com-
lement and perivascular IgM and the presence of an
ntense inﬂammatory inﬁltrate composed predominantly of
acrophages, granulocytes and eosinophils in demyelinating
esions in neuromyelitis optica autopsy cases, conﬁrming the
mportance of humoral immunity in the pathophysiology of
euromyelitis optica.10
In a retrospective study covering a 15-year period, Jef-
ery et al. evaluated nine children with neuromyelitis optica.
ll children had had a viral infection prior to neuromyelitis
ptica symptoms. Bilateral optic neuritis was a common ﬁnd-
ng, observed in 89% of children, and all children exhibited a
onophasic course.3 However, antibody-positive Devic’s dis-
ase is not typically associated with a monophasic illness but
oes display a very rapid progressive course.
Our patient presented the clinical characteristics described
bove, magnetic resonance imaging abnormalities and thePlease cite this article in press as: Fraga MM, et al. Devic’s disease in an ado
http://dx.doi.org/10.1016/j.rbre.2014.12.004
resence of antibody anti-aquaporin-4. She has the recurrent
orm of the disease and already has irreversible visual impair-
ent. 6;x  x x(x x):xxx–xxx 3
Neuromyelitis optica ﬁndings may appear in patients with
other autoimmune, inﬂammatory and infectious diseases
with some reports in adults and children.11 Although the
authors do not suggest a possible explanation for these
associations, infectious agents can trigger the autoimmune
process.
There is no consensus on the treatment of recur-
rent neuromyelitis optica. Several alternatives have been
reported. Relapses are treated with oral prednisone,
methylprednisolone, intravenous immunoglobulin and
plasmapheresis.12 Maintenance therapy involves monthly
intravenous immunoglobulin13 and rituximab.14 Recently,
two studies showed that treatment with azathioprine
plus prednisone or mofetil mycophenolate halts disease
progression.12,15
After the ﬁrst outbreak, this patient received pulse therapy
with methylprednisolone and maintenance with prednisone
and azathioprine. After the second outbreak, the use of
methylprednisolone pulse therapy with monthly intravenous
immunoglobulin, in addition to maintaining prednisone and
azathioprine, was preferred.
The onset of atypical neurological symptoms during the
course of a rheumatic disease should call attention to the pos-
sibility of an association with this autoimmune disease. In the
case presented herein, the appearance of unusual visual and
motor symptoms in a patient with juvenile dermatomyositis
readily led to clinical suspicion, and laboratory tests conﬁrmed
the associated neurological disease.
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